申请人:CELLIX BIO PRIVATE LIMITED
公开号:US11225464B2
公开(公告)日:2022-01-18
The disclosures herein provide compounds of formula I, formula II, formula III, formula IV, formula V and formula VI or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal polyps or its associated complications.
本文公开了式 I、式 II、式 III、式 IV、式 V 和式 VI 的化合物或其药物可接受盐,以及它们的多晶型物、对映体、立体异构体、溶液和水合物。这些盐类可配制成药物组合物。这些药物组合物可配制成口服、口腔、直肠、局部、透皮、透粘膜、锭剂、喷雾剂、静脉注射、口服溶液、颊粘膜层片剂、肠外给药、糖浆或注射剂。此类组合物可用于治疗胃肠道息肉或其相关并发症。